Vertex Pharmaceuticals (VRTX) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026Business and milestones
Q3 results showed balanced CF growth in the U.S. and internationally; JOURNAVX and CASGEVY remained on track to contribute more than $500 million in 2026 against revenue guidance above $13 billion.
Key upcoming milestones include the Nov. 30, 2026 PDUFA date for povetacicept in IgAN and phase II proof-of-concept results in myotonic dystrophy type 1 before year-end 2026.
The portfolio now spans CF, sickle cell disease, acute pain and acromegaly, with IgAN planned as the first renal launch.
Renal pipeline and IgAN launch
Povetacicept is launch-ready, with FDA review events proceeding on track for the Nov. 30, 2026 PDUFA date.
At 36 weeks, data showed >50% proteinuria reduction, >80% hematuria resolution and >40% of patients meeting KDIGO guidelines; no head-to-head comparisons were available.
Monthly at-home auto-injector dosing uses a 0.46 mL dose with lower viscosity than peers; serious infection rates were 0.5% in both the placebo and povetacicept arms.
Expected monitoring and labeling are consistent with peers; the trial checked IgG monthly, while cross-trial monitoring differences limit direct comparisons.
The U.S. has 160,000 biopsy-confirmed diagnosed IgAN patients; more than 90% of the trained sales force has prior nephrology experience, with payer discussions and patient support preparations underway.
Inaxaplin AMPLITUDE interim analysis is expected in Q1 2027; the 48-week eGFR-slope result could support a U.S. accelerated-approval path if positive.
In APOL1-mediated kidney disease, earlier studies showed proteinuria reductions in the mid-to-high 40% range; the potential U.S. population is ~150,000, expanding to ~250,000 with comorbidities such as type 2 diabetes.
Most potential APOL1-mediated kidney disease patients are undiagnosed; a companion diagnostic and genetic testing outreach are anticipated to support a precision-medicine launch.
Pain franchise
Two phase III diabetic peripheral neuropathy studies are on track to complete enrollment by year-end 2026, with results expected by mid-2027; both are 12-week, placebo-controlled studies, and one includes pregabalin as a comparator.
The phase II study showed a two-point NPRS reduction; phase III success will depend substantially on managing the placebo effect.
A NaV1.7 program remains late preclinical; entry into clinical testing is hoped for in 2027, likely directly in combination with NaV1.8 inhibition.
JOURNAVX prescriptions are on track to more than triple in 2026 vs. 2025; Q3 revenue was slightly above flat sequentially as reimbursement conversion remained a constraint.
Free-drug patient support is planned to continue through mid-2027 and then phase out gradually; gross-to-net is expected to normalize to the mid-50% range by mid-2027.
Latest events from Vertex Pharmaceuticals
- Revenue rose 12% as new franchises broadened growth; higher costs weighed on earnings.VRTX
Q3 2026 - Povetacicept cut IgAN proteinuria 52.0%; AMPLITUDE interim data target early 2027.VRTX
American Society of Nephrology (ASN) Kidney Week 2026 - Diversified pipeline, regulatory catalysts, and new assets drive growth beyond cystic fibrosis.VRTX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead.VRTX
Morgan Stanley 24th Annual Global Healthcare Conference - Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook.VRTX
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 12% to $3.33B; guidance raised; $10B Crinetics acquisition announced.VRTX
Q2 2026 - $10B acquisition adds leading endocrine assets, accelerating growth and portfolio diversification.VRTX
M&A announcement - Q3 revenue up 12% to $2.77–$2.8B; guidance raised as pipeline and launches drive growth.VRTX
Q3 2024 - 2024 revenue up 12% with new launches; Alpine charge led to GAAP loss, but 2025 outlook strong.VRTX
Q4 2024